Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Protagonist Therapeutics
Biotech
Protagonist prefers $400M from Takeda over rusfertide US profits
While the FDA mulls whether to approve Protagonist’s hematology asset, the biopharma is planning to pocket $400 million rather than split profits.
James Waldron
Feb 26, 2026 10:00am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
J&J eyes takeover of immunology partner Protagonist: WSJ
Oct 10, 2025 2:30pm
J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial
Sep 17, 2025 9:45am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu
Mar 10, 2025 7:30am
